ALSO READShilpa Medicare gets EIR from USFDA for Jadcherla facility Shilpa Medicare receives EIR report for facility in Jadcherla in Telangana Shilpa Med gets 10 observations from USFDA for Jadcherla plant Shilpa Medicare standalone net profit rises 15.73% in the June 2017 quarter Shilpa Medicare consolidated net profit rises 73.94% in the June 2017 quarter
Receives 10 observations under Form 483Shilpa Medicare has received 483 Observations from the United States Food & Drug Administration (USFDA) in relation to SEZ Formulation Facilities situated at Jadcherla, Telangana (near Hyderabad) as under;
a) Total 10 observations were cited during the close up meeting.
b) 7 observations are improvement in procedures and practices.
c) 3 observations are related to setting of analytical specifications, test procedures and method validation.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)